Trial · NCT01358877
Results by group636
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 636
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 6 Years | 90.56 | 95% Confidence Interval 89.35 to 91.77 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 6 Years | 87.76 | 95% Confidence Interval 86.40 to 89.13 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 8 Years | 88.43 | 95% Confidence Interval 87.10 to 89.76 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 8 Years | 85.76 | 95% Confidence Interval 84.32 to 87.21 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 10 Years | 87.17 | 95% Confidence Interval 85.77 to 88.57 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 10 Years | 83.82 | 95% Confidence Interval 82.29 to 85.36 | Estimate of percentage of participants |
| Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 7.9 | percentage of participants | ||
| Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 9.6 | percentage of participants | ||
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 93.50 | 95% Confidence Interval 92.49 to 94.51 | Estimate of percentage of participants | |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 92.51 | 95% Confidence Interval 91.43 to 93.58 | Estimate of percentage of participants | |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 6 Years | 89.31 | 95% Confidence Interval 88.03 to 90.59 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 6 Years | 86.42 | 95% Confidence Interval 85.00 to 87.44 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 8 Years | 87.08 | 95% Confidence Interval 85.69 to 88.48 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 8 Years | 83.82 | 95% Confidence Interval 82.29 to 85.34 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 10 Years | 85.23 | 95% Confidence Interval 83.74 to 86.71 | Estimate of percentage of participants |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 10 Years | 81.31 | 95% Confidence Interval 79.69 to 82.93 | Estimate of percentage of participants |
| Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 8.0 | percentage of participants | ||
| Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 9.8 | percentage of participants | ||
| Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Pertuzumab + Trastuzumab + Chemotherapy | 93.42 | 95% Confidence Interval 92.40 to 94.43 | Estimate of percentage of participants | |
| Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | Placebo + Trastuzumab + Chemotherapy | 92.29 | 95% Confidence Interval 91.21 to 93.38 | Estimate of percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01358877/results